Analytical Data
-
Gene name
E3L
- Application
-
Alternative Names
E3L；DAL1；KIAA0987；Band 4.1-like Protein 3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P21605
-
Expression Region
1-190
-
AA Sequence
MSKIYIDERS NAEIVCEAIK TIGIEGATAA QLTRQLNMEK REVNKALYDL QRSAMVYSSD DIPPRWFMTT EADKPDADAM ADVIIDDVSR EKSMREDHKS FDDVIPAKKI IDWKGANPVT VINEYCQITR RDWSFRIESV GPSNSPTFYA CVDIDGRVFD KADGKSKRDA KNNAAKLAVD KLLGYVIIRF
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The E3L protein, derived from the vaccinia virus, has garnered significant attention in the field of molecular biology and virology due to its role in the virus's ability to evade the host immune response. E3L functions as an E3 ubiquitin ligase, which mediates the attachment of ubiquitin molecules to target proteins, playing a critical part in regulating various cellular processes, including apoptosis and immune signaling pathways. Research into E3L has revealed its capability to inhibit the activation of interferon (IFN) responses, a crucial component of the innate immune system that serves as the first line of defense against viral infections. Understanding the molecular mechanisms underlying E3L's actions may provide insights into viral pathogenesis and the development of novel antiviral strategies. Furthermore, the unique properties of E3L make it a potential tool for therapeutic applications, including gene editing and targeted drug delivery systems. As researchers continue to explore the intricate interactions between E3L and host cellular machinery, the findings could pave the way for innovative approaches to combat viral diseases and improve vaccine efficacy.
